Prostate cancer is one of the most common cancers among men. Patients are determined to have prostate cancer primarily based on [Prostate-Specific Antigen, or] PSA, a cancer factor in blood. However, as diagnostic accuracy is as low as 30%, a considerable number of patients undergo additional invasive biopsy and thus suffer from resultant side effects, such as bleeding and pains.
The Korea Institute of Science and Technology (KIST) announced that the collaborative research team led by Dr. Kwan Hyi Lee from the Biomaterials Research Center and Professor In Gab Jeong from Asan Medical Center developed a technique for diagnosing prostate cancer from urine within only twenty minutes with almost 100% accuracy. The research team developed this technique by introducing a smart AI analysis method to an electrical-signal-based ultrasensitive biosensor.
As a noninvasive method, a diagnostic test utilizing urine is convenient for patients and does not need invasive biopsy, thereby diagnosing cancer without side effects.
“For patients who need surgery and/or treatments, cancer will be diagnosed with high accuracy by utilizing urine to minimize unnecessary biopsy and treatments, which can dramatically reduce medical costs and medical staff’s fatigue,” Professor Jeong at Asan Medical Center said.